Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects (Q39508210)

12 September 2017

title

Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects (English)

1 reference

12 September 2017

Guang-Hong Tan

1 reference

12 September 2017

Yue-Nan Li

1 reference

12 September 2017

Feng-Ying Huang

1 reference

12 September 2017

Hua Wang

1 reference

12 September 2017

Rui-Zhen Bai

1 reference

12 September 2017

Jie Jang

1 reference

12 September 2017

publication date

1 January 2007

1 reference

Immunological Investigations

12 September 2017

published in

1 reference

12 September 2017

1 reference

12 September 2017

1 reference

12 September 2017

page(s)

423-440

1 reference

Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

DNA vaccines: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

DNA vaccine strategies: candidates for immune modulation and immunization regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

CD105 is important for angiogenesis: evidence and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Clinical applications of angiogenic growth factors and their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Endoglin modulates cellular responses to TGF-beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820130701361103

10.1080/08820130701361103

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference